  |
 | Up a level |
Cristofanilli, Massimo and Rugo, Hope S. and Im, Seock-Ah and Slamon, Dennis J. and Harbeck, Nadia and Bondarenko, Igor and Masuda, Norikazu and Colleoni, Marco and DeMichele, Angela and Loi, Sherene and Iwata, Hiroji and O’Leary, Ben and André, Fabrice and Loibl, Sibylle and Bananis, Eustratios and Yuan Liu, Yuan Liu and Huang, Xin and Kim, Sindy and Frean, Maria Jose Lechuga and Turner, Nicholas C. (2022) Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clinical Cancer Research, 28 (16). pp. 3433-3442. ISSN 1078-0432 (print), 1557-3265 ( online)
Finn, Richard S. and Boer, Katalin and Bondarenko, Igor and Patel, Ravindranath and Pinter, Tamas and Schmidt, Marcus and Shparyk, Yaroslav V. and Thummala, Anu and Voitko, Nataliia and Bananis, Eustratios and McRoy, Lynn and Wilner, Keith and Huang, Xin and Kim, Sindy and Slamon, Dennis J. and Ettl, Johannes (2020) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first‑line treatment of ER+/HER2− advanced breast cancer (PALOMA‑1, TRIO‑18). Breast Cancer Research and Treatment, 183. pp. 419-428. ISSN 0167-6806 (print); 1573-7217 (online)
Finn, Richard S. and Crown, John and Lang, Istvan and Boer, Katalin and Bondarenko, Igor and Kulyk, Sergey O. and Ettl, Johannes and Patel, Ravindranath and Pinter, Tamas and Schmidt, Marcus and Shparyk, Yaroslav V. and Thummala, Anu and Voytko, Nataliya L. and Fowst, Camilla and Huang, Xin and Kim, Sindy and Slamon, Dennis J. (2017) Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2–advanced breast cancer (PALOMA-1; TRIO-18). Journal of Clinical Oncology, 35 (15). p. 1001. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)
